Superior GVHD ‐Free, Relapse‐Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation
American Journal of Hematology · 2025
DOI: 10.1002/ajh.70008 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Hematology, 2025. Verfasst von Yishan Ye und 20 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China. Hauptthemen laut MEDLINE: Leukemia, Myeloid, Acute, Graft vs Host Disease, Hematopoietic Stem Cell Transplantation, Cyclophosphamide. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 30 Literaturangaben. Gefördert von: "Pioneer" and "Leading Goose" R&D Program of Zhejiang, Zhejiang University Global Partnership Fund, National Natural Science Foundation of China.
Abstract (Originalsprache)
Donor preference for acute myeloid leukemia (AML) patients transplanted in second complete remission (CR2) remains unclear, and hematopoietic cell transplantation (HCT) with post‐transplant cyclophosphamide (PTCy) from a haploidentical donor (HAPLO) merits attention. Data of 3878 adult AML patients receiving a first allo‐HCT in CR2 from the European Society of Blood and Marrow Transplantation registry between 2010 and 2022 were analyzed. Univariate analyses and Cox regression models were used. Results of HCTs from 803 HAPLO PTCy, 1271 matched sibling donor (MSD), and 1804 matched unrelated donor (MUD) were analyzed. A higher proportion (80.7%) of patients with European LeukemiaNet (ELN2022) intermediate−/adverse‐risk cytogenetics received an allo‐HCT from HAPLO PTCy than from either MUD (79.6%) or MSD (70.2%). On multivariate analysis, HAPLO PTCy grafts (hazard ratio [HR] = 0.65, 95% confidence interval [CI] 0.51–0.82; p < 0.001) were associated with a lower relapse incidence (RI) compared with MSD HCTs, although non‐relapse mortality was higher (HR = 1.77, 95% CI 1.34–2.34; p < 0.001). No difference was observed with respect to leukemia‐free survival and graft‐versus‐host disease (GVHD)‐free, relapse‐free survival (GRFS) for HAPLO PTCy compared to MSD grafts. Notably, HAPLO PTCy HCT was associated with significantly lower RI (HR = 0.64, 95% CI 0.48–0.82; p < 0.001), chronic GVHD (cGVHD) (HR = 0.64, 95% CI 0.51–0.81; p < 0.001) and extensive cGVHD (HR = 0.47, 95% CI 0.34–0.66; p < 0.001) incidences compared to MUD HCTs. Collectively, HAPLO PTCy HCT was associated with superior GRFS (HR = 0.81, 95% CI 0.68–0.95; p = 0.013) than MUD HCT. For AML patients in CR2, HAPLO PTCy HCT is associated with lower RI and cGVHD, leading to superior GRFS compared with MUD HCTs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China.
- EBMT Paris Office, Hôpital Saint Antoine 184, Paris, France.
- CHU de Lille, Lille, France.
- Saint-Louis Hospital, BMT Unit, Paris, France.
- Transplantation & Cellular Therapy, Department of Hematology, Institut Paoli Calmettes, Management Sport Cancer Lab, Luminy, Aix Marseille University, Marseille, France.
- Oslo University Hospital, Oslo, Norway.
ORCID-Profile: Yishan Ye, Ali Bazarbachi, Lin Li, He Huang
Förderung
- "Pioneer" and "Leading Goose" R&D Program of Zhejiang
- Zhejiang University Global Partnership Fund
- National Natural Science Foundation of China
Zitieren
APA
Ye, Y., Labopin, M., Yakoub-Agha, I., Socié, G., Blaise, D., Gedde-Dahl, T., Blau, I. W., Raiola, A. M., Byrne, J., Daguindau, E., Labussière-Wallet, H., Huynh, A., Bazarbachi, A., Nagler, A., Brissot, E., Li, L., Luo, Y., Shi, J., Mohty, M., …, & Ciceri, F. (2025). Superior GVHD ‐Free, Relapse‐Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology. https://doi.org/10.1002/ajh.70008
Vancouver
Ye Y, Labopin M, Yakoub-Agha I, Socié G, Blaise D, Gedde-Dahl T, et al. Superior GVHD ‐Free, Relapse‐Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. American Journal of Hematology. 2025. doi:10.1002/ajh.70008
BibTeX
@article{Ye2025,
author = {Ye, Yishan and Labopin, Myriam and Yakoub-Agha, Ibrahim and Socié, Gérard and Blaise, Didier and Gedde-Dahl, Tobias and Blau, Igor Wolfgang and Raiola, Anna Maria and Byrne, Jennifer and Daguindau, Etienne and Labussière-Wallet, Hélène and Huynh, Anne and Bazarbachi, Ali and Nagler, Arnon and Brissot, Eolia and Li, Lin and Luo, Yi and Shi, Jimin and Mohty, Mohamad and Huang, He and Ciceri, Fabio},
title = {Superior GVHD ‐Free, Relapse‐Free Survival for Haploidentical Transplant With PTCy Than Matched Unrelated Donor for AML Patients Transplanted in Second Complete Remission: A Study From the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation},
journal = {American Journal of Hematology},
year = {2025},
doi = {10.1002/ajh.70008}
}
EUVIMED